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Abstract
Background: Prevention of poxvirus infection is a topic of great current interest. We report
inhibition of vaccinia virus in cell culture by porphyrins and phthalocyanines. Most previous work
on the inhibition of viruses with tetrapyrroles has involved photodynamic mechanisms. The current
study, however, investigates light-independent inhibition activity.
Methods: The Western Reserve (WR) and International Health Department-J (IHD-J) strains of
vaccinia virus were used. Virucidal and antiviral activities as well as the cytotoxicity of test
compounds were determined.
Results: Examples of active compounds include zinc protoporphyrin, copper hematoporphyrin,
meso(2,6-dihydroxyphenyl)porphyrin, the sulfonated tetra-1-naphthyl and tetra-1-
anthracenylporphyrins, selected sulfonated derivatives of halogenated tetraphenyl porphyrins and
the copper chelate of tetrasulfonated phthalocyanine. EC50 values for the most active compounds
are as low as 0.05 µg/mL (40 nM). One of the most active compounds was the neutral meso(2,6-
dihydroxyphenyl)porphyrin, indicating that the compounds do not have to be negatively charged to
be active.
Conclusions: Porphyrins and phthalocyanines have been found to be potent inhibitors of infection
by vaccinia virus in cell culture. These tetrapyrroles were found to be active against two different
virus strains, and against both enveloped and non-enveloped forms of the virus, indicating that these
compounds may be broadly effective in their ability to inhibit poxvirus infection.
Introduction
Smallpox, while not found in the world's population at
present, remains a potential health hazard especially due
to the possibility of its use as a bioweapon [1–5]. There is
currently no accepted treatment for smallpox, although a
number of agents have been evaluated [6]. Therefore, new
therapeutic or virucidal agents could have great utility in
slowing both the progression and spread of the disease in
an epidemic situation. In the present study, we have inves-
tigated the potential of porphyrins (Por) and phthalocy-
anines (Pc) to prevent infection by vaccinia virus in cell
culture.
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Materials and Methods
Porphyrins and phthalocyanines
Porphyrins were obtained from Midcentury Chemicals
(Chicago, Illinois) or Frontier Scientific (Logan, Utah)
and used as received. Porphyrin designations are as fol-
lows: PP, protoporphyrin IX; HP, hematoporphyrin IX;
TPP,  meso-tetraphenylporphine; TNapPS, sulfonated
5,10,15,20-tetra-naphthalen-1-yl-porphyrin; TAnthPS,
sulfonated 5,10,15,20-tetra-anthracen-9-yl-porphyrin.
Other porphyrins are tetraphenylporphyrin derivatives,
e.g., TPP2F is tetraphenylporphyrin with a fluoro group at
the 2-position on each phenyl ring. An "S" at the end of
the name indicates that the parent porphyrin was sul-
fonated. In most cases, these are mixtures with variable
numbers of sulfonates and/or positions of the sulfonates
on the ring. The sulfonated copper phthalocyanine [sold
as CuPcS(3,4',4",4"')] was purchased from Aldrich.
Cell lines and virus strains
CV-1, BSC-40 and TK-143B cells were maintained in Dul-
becco's modified Eagle's medium (DMEM) supplemented
with 10% fetal bovine serum (FBS) and incubated at
37°C, 5% CO2. CV-1 cells were utilized for virus titer
determinations and TK-143B cells were used in virus stock
preparations. HeLa S3 cells were grown at 37°C in RPMI
1640 culture medium supplemented with 10% FBS and
the antibiotics penicillin and streptomycin.
Growth of vaccinia virus (VV)
Two strains of vaccinia virus (VV) were used in this study:
the Western Reserve (WR) and International Health
Department-J (IHD-J) strains. The WR strain, produced by
Virotech International (Rockville, MD), was a gift from
Dr. Mark Feinberg (Emory University). The IHD-J strain
was grown as described previously [7]. TK-143B cells,
grown in roller bottles, were infected with the WR strain
of the virus and incubated for 2 days at 37°C. The cells
were collected, resuspended in a buffered solution of 10
mM Tris-HCl (pH 9) and homogenized with 20 strokes in
a Dounce homogenizer. Large debris and nuclei were sed-
imented by centrifugation at 1,400 rpm for 5 min. The
supernatant was collected and trypsin (250 µg/mL)
added. This was then loaded on a 36% sucrose cushion
and the virus pelleted by centrifugation at 13,500 rpm for
80 min using a Beckman SW28 rotor. Extracellular parti-
cles of IHD-J were obtained by infecting TK-143B cells.
After 24 h incubation at 37°C, the culture medium was
pre-cleared and the virus was concentrated by centrifuga-
tion at 13,500 rpm for 80 min in a SW28 rotor and resus-
pended in 1 mM Tris-HCl (pH 9).
Prevention of virus infection
A plaque assay was used to determine the ability of test
compounds to prevent infection. Compound stock solu-
tions, 5 mg/mL, were diluted 10-fold in DMEM without
FBS and mixed with virus particles to five final concentra-
tions: 50, 10, 2, 0.4 and 0.08 µg/mL. After 1 h incubation
(in the dark) the virus-drug mixture was diluted 10-fold in
DMEM (without FBS) to 500 µL and 100 µL added to each
well of confluent CV-1 or BSC-40 cells grown in 24-well
plates. This afforded 200 pfu/well (1 × 10-3 pfu/cell). Fol-
lowing virus-drug adsorption onto the monolayer, 1 h at
37°C, cell monolayers were washed twice PBS to remove
residual virus-drug mixture. New growth medium supple-
mented with 2.5% FBS was then added to each well.
A plaque assay was used to determine the quantity of
infectious particles remaining after drug treatment. Two
days after infection, the growth medium was removed and
the cells washed twice with PBS. A solution of 0.1% crystal
violet, 10% formaldehyde in phosphate buffered saline
(PBS) was then added to the wells. After 30 min incuba-
tion, the stain was removed and the wells washed with
PBS and allowed to dry. The number of plaques was then
determined and activity calculated based on the reduction
in average number of plaques, in wells where the com-
pound was pre-incubated with the virus, compared to the
control wells inoculated with untreated virus. As an alter-
native to the liquid overlay, agar overlays were also inves-
tigated. Similar results were obtained with both assays.
Hence, further plaque assays were done using liquid
overlays.
EC50 values were calculated as response = min + (max-
min)/(1+10 [exp(log[drug]-logEC50)] using Kaleidagraph
(Synergy Software, Reading, Pennsylvania). Reported
EC50 values are the average and standard deviation of
three separate determinations, each replicated three times.
Inhibition of virus yield
Confluent monolayers of CV-1 cells were infected with 5
× 105 pfu/well (2.5 pfu/cell) of WR for 2 h at 37°C. The
cells were then washed twice with PBS to remove any
residual virus. Compound stock solutions, 5 mg/mL, were
diluted in DMEM with 2.5% FBS to final concentrations
of 50 or 25 µg/mL. This media containing compounds
(500 µL) was then added to the cells. At 16 h post-infec-
tion, cell monolayers and culture medium were harvested
and subjected to several cycles of freeze/thawing to release
intracellular and extracellular virus particles. A plaque
assay on CV-1 cells was used to determine the virus titer.
CV-1 cells were infected with the virus inoculum for 1 h;
the growth medium was removed and 2.5% FBS in
DMEM added to the cells. After 2 days, the cells were
washed with PBS and later stained with a solution of 0.1%
crystal violet, 10% formaldehyde in PBS, and the viral
plaque number was counted. To determine if viral inacti-
vation occurs after cell lysis, the cell monolayers were
washed three times with DMEM to remove theBMC Infectious Diseases 2003, 3 http://www.biomedcentral.com/1471-2334/3/9
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compounds then harvested and subjected to several cycles
of freeze/thawing to release intracellular virus particles.
Cell proliferation assay
Cell proliferation was measured by [3H]-thymidine
uptake [8]. HeLa S3 cells (3 × 104 cells/well) were incu-
bated in 96-well plates in the presence of varying concen-
trations of the tetrapyrroles for 2 days at 37°C, after which
3H-TdR (1 µCi/well) was added. The cells were further
incubated for 16 h, then harvested and 3H-TdR incorpora-
tion monitored by using a liquid scintillation counter.
Data are from a single experiment.
Cytotoxicity of active tetrapyrroles
CV-1 and BSC-40 cells were seeded at a concentration of
3.5 × 104 cells/well in a 96-well plate and allowed to
attach overnight, after which they were ~80% confluent.
Compounds in DMEM with 10% FBS were added to the
cells. After 2 days, a trypan blue viability assay [9] was per-
formed. The 50% cytotoxic concentration (CC50) is the
concentration required to reduce viable cell numbers by
50% relative to untreated control cell numbers. This was
determined by incubation in growth medium containing
serial dilutions of compounds in the range of 50 – 2000
µg/mL for 2 days, after which the viable cell numbers were
determined. To determine the effect of the compounds on
cell proliferation, after 24 h incubation, the cells were
washed and further incubated in the absence of the com-
pounds for 1 day, and then a trypan blue assay was done.
Data are from a single experiment.
Cytostatic activity
CV-1 cells were seeded at 3.5 × 103 cells/well (in growth
medium) in a 96-well plate and allowed to attach over-
night; the compounds (in growth medium) were then
added. Following a 24 h incubation, the cells were
counted.
Results
Initial screening of porphyrins and phthalocyanines (Fig-
ure 1) involved more than 100 different compounds.
These compounds were pre-incubated with the virus and
then the mixture was inoculated on CV-1 cells and resid-
ual virus titers were determined by plaque assay. Based on
the results obtained, we were able to determine the most
active compounds, that is, compounds at 50 µg/mL that
inactivated the virus completely (no plaques seen) (Figure
2). These were chosen as candidates for further study.
Approximately 20 natural porphyrins (based on the pro-
toporphyrin ring skeleton of hemin) were evaluated. In
general, structures with the hematoporphyrin ring (i.e.,
hydroxyethyl groups at the 2- and 4-positions, see CuH-
PIX in Figure 1) were found to be more active than struc-
tures with the protoporphyrin (see ZnPPIX in Figure 1),
mesoporphyrin, deuteroporphyrin or deuteroporphyrin
disulfonic acid rings (ethyl, hydrogen or sulfonate at posi-
tions 2 and 4, respectively). CuHPIX and ZnPPIX were
evaluated in more detail. CuHPIX was more active than
ZnPPIX [e.g., EC50 values of 1.5 vs. 25.7 µg/mL for IHD-J
(in CV-1 cells)] but neither was as active as the sulfonated
porphyrins (vide infra). The ability of these compounds to
prevent infection was also compared in BSC-40 cells. Gen-
erally, the EC50 data obtained from both cell lines were of
the same order of magnitude; however, in the BSC-40 cell
line, the WR strain of the virus showed a hundred-fold
greater sensitivity to CuHPIX as compared with CV-1 cells
(Table 1).
A large number of sulfonated tetraphenylporphyrin deriv-
atives was also evaluated. A series of 15 metal chelates of
tetraphenylporphyrin tetrasulfonate (TPPS4) was tested,
but none showed more than 50% activity at 50 µg/mL
using either the WR or IHD-J strains; these candidates
therefore were not pursued. A series of 12 tetraphenylpor-
phyrin derivatives made via sulfonation of the 2-F, Cl and
Br, the 3-F and Cl and the 4-F and Cl tetraphenylporphy-
rins was evaluated. Many of these derivatives completely
blocked infection by both strains at concentrations of 50
µg/mL (Figure 3). TPP2ClS and TPP2FS were studied in
more detail. These two derivatives had similar activities
(within a factor of 4) in the WR and IHD-J assays. A series
of sulfonated derivatives of the 2,6-difluoro and 2,6-
dichlorotetraphenylporphyrins was also studied. The par-
ent compounds and the Co(III) chelate of the difluoro-
porphyrin completely inhibited infection at 50 µg/mL;
the Co(III) chelate had EC50 values of 1.6 (CV-1) and 0.74
µg/mL (BSC-40) in the WR assay and 0.44 µg/mL (CV-1)
in the IHD-J assay. The other compounds tested were less
active, i.e., at 50 µg/mL, they inactivated the virus by less
than 50%. Four non-halogenated porphyrin derivatives
with aryl side chains, TNapS, TAnthS, TPP[2,6-(OH)2]
and TPP4OMeS, had high activity (Table 1). All of these
had EC50 values of < 5 µg/mL in both assays. TNapS and
TAnthS were more active against the IHD-J than WR strain
(Table 1) using CV-1 cells. TPP[2,6-(OH)2] also had high
activity. EC50 values were 0.17 (CV-1) and 0.19 (BSC-40)
µg/mL for the WR assay; and 0.7 (CV-1) and 0.32 µg/mL
(BSC-40) in the IHD-J assay. TPP[2,6-(OH)2] is a neutral
compound with eight hydroxyl groups (Figure 1); this
may give it amphiphilic properties that could play a role
in blocking infection.
Approximately 25 sulfonated phthalocyanines (PcS) were
evaluated. Only the copper and chromium PcS were able
to inhibit viral infection. The copper phthalocyanine sul-
fonate only had an EC50 of approximately 50 µg/mL in the
WR assay in both cell lines. It was somewhat more active
in the IHD-J assays, but the sulfonated phthalocyanines
were not studied further.BMC Infectious Diseases 2003, 3 http://www.biomedcentral.com/1471-2334/3/9
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Since there are major differences in surface antigens, and
presumably in the host cell receptors, between the intrac-
ellular and extracellular particles of VV [10–12], we also
compared the sensitivity of the two forms to the com-
pounds to be tested. Generally, the compounds tested
were highly effective against both forms (Table 1). Com-
parison of the intracellular mature virion (IMV, third col-
umn in Table 1) and extracellular enveloped virion (EEV)
forms of the IHD-J strain showed differences in activity of
some compounds in blocking infection by the two forms
of the virus. These results suggest that the tetrapyrroles
may be binding to different components on the surface of
the two forms of the virus and thus show differences in
efficiency of preventing virus infection.
Figure 1
Structures of tetrapyrroles used in this study.
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The active compounds exhibited very low to moderate
toxicity in assays for their effects on cell viability (Table 2).
Therapeutic ratios, calculated as CC50/EC50, were found to
be in a range from 64 – 1400, with the exception of
ZnPPIX, for which the ratios were in the range of 1 – 3.
The compounds were also tested in CV-1 cells and a
human cell line (HeLaS3) for their effect on cell growth
(Table 3). The compounds tested generally inhibited CV-
1 cell growth at high concentrations, and 3H-thymidine
uptake in HeLa cells by 50% only at concentrations above
20 µg/mL except for Co(III)TPP(2,6-F2)S (CC50 < 5 µg/
mL).
The ability of a number of tetrapyrroles to inhibit virus
replication was determined in CV-1 cells infected with the
WR strain in the absence of compounds. Following virus
Figure 2
Prevention of virus infection. TPP[2,6-(OH)2], 50 µg/mL, was incubated with vaccinia virus for 1 h, and then applied to cells. 
Following virus adsorption, the residual virus-drug mixture was removed and new growth medium added. Plaques were visual-
ized after 2 days (as described in Materials and Methods). (a) WR and (b) IHD-J incubated with CV-1 cells in the absence and 
presence of TPP [2,6-(OH)2].BMC Infectious Diseases 2003, 3 http://www.biomedcentral.com/1471-2334/3/9
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adsorption (2 h), compounds in growth medium were
added to the cells. After 16 h post-infection, cells and
media were collected, virus was released by freezing and
thawing and virus yields determined by plaque assay.
Reduction of virus yield was observed with all compounds
assayed (Table 4), with most compounds resulting in 95
– 99% reduction at 50 µg/mL. These results indicate that
infectious virus production is being inhibited by these
compounds.
These results were compared to those of other experi-
ments in which the compounds were removed before viral
titration was done (Table 5). The effect on viral yield was
found to be significantly reduced when the compounds
were removed prior to harvest, indicating that the inhibi-
tory effect occurs predominantly after viral release. Using
a lower moi (0.001 pfu/cell), and removing the
compounds before the viral harvest resulted in reduction
of viral yields by as much as 98% (Table 6), indicating that
the compounds block multiple cycle replication of the
virus. Inhibition of virus spread by these compounds has
also been observed when the tetrapyrroles were included
in the overlay medium in a plaque assay. After 44 h, the
cell monolayers were stained and the plaque numbers
determined. We observed substantial reductions in
plaque numbers and size (data not shown) indicating
inhibition of both virus infection and spread.
Discussion
Photoinactivation of viruses by diamagnetic porphyrins
and phthalocyanines has been widely studied [13–20].
Photoactivation involves absorption of light by the
Table 1: Prevention of vaccinia virus infection by tetrapyrroles.
Compound EC50 (µg/ml)
WR IHD-J IHD-J (EEV)
CV-1 BSC-40 CV-1 CV-1 BSC-40
ZnPPIX 15 ± 12 26 ± 3.4 38 ± 7.8
CuPcS(3444) 29 ± 13 >50 14 ± 5.3 8.2 ± 1.3 50 ± 7
TNapPS 0.83 ± 0.1 0.71 ± 0.3 1.0 ± 0.1
TAnthPS 0.30 ± 0.1 0.15 ± 0.03 0.05 ± 0.0005 0.2 ± 0.1 0.55 ± 0.14
TPP[2,6-(OH)2] 0.17 ± 0.01 0.19 ± 0.03 0.59 ± 0.1 0.7 ± 0.2 0.32 ± 0.11
CuHPIX 7.8 ± 0.9 0.03 ± 0.01 1.5 ± 0.4 1.1 ± 0.4 0.32 ± 0.13
Co(III)TPP(2,6-F2)S 1.6 ± 0.1 0.74 ± 0.38 0.44 ± 0.02 6.1 ± 1.6 5.6 ± 2.8
TPP4OMeS 1.0 ± 0.1 1.3 ± 0.4 0.5 ± 0.1
TPP2ClS 1.0 ± 0.2 1.0 ± 0.1 0.7 ± 0.1
TPP2FS 1.3 ± 0.3 0.26 ± 0.1 1.1 ± 0.5
Table 2: Therapeutic indices of selected tetrapyrroles.
Compound Therapeutic index
CC50 (µg/mL)a WR IHD-J IHD-J (EEV)
ZnPPIX 50 3 2 1
CuPcS(3444) 2000 70 140 240
TNapPS4 500 600 700 500
TAnthPS4 50 170 1000 250
TPP[2,6-(OH)2] 50 290 85 71
CuHPIX 500 64 330 460
Co(III)TPP(2,6-F2)S 500 310 1100 82
TPP4OMeS 300 300 230 600
TPP2ClS 1000 1000 1000 1400
TPP2FS 200 150 770 180
aCV-1 cell viability was determined by trypan blue assay as described in Materials and Methods.BMC Infectious Diseases 2003, 3 http://www.biomedcentral.com/1471-2334/3/9
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Table 3: Effects of tetrapyrroles on cell viability and growth.
Compound CC50 (µg/mL)
Cytostatic activitya Cell proliferationb
ZnPPIX 370 25
CuPcS(3444) > 1000 > 500
TNapPS 400
TAnthPS 350 120
TPP[2,6-(OH)2] 90 20
CuHPIX 36
Co(III)TPP(2,6-F2)S 300 < 5
aCV-1 cells were seeded at 3.5 × 103 cells/well and allowed to attach overnight, then the compounds (in growth medium) added. Following 24 h 
incubation, the cells were counted. bThese results were obtained by measuring 3H-thymidine uptake using HeLa S3 cells.
Table 4: Reduction of vaccinia virus yield by selected tetrapyrroles.a
Compound Concentration
25 µg/mL 50 µg/mL
titer (pfu/mL) % inhibition titer (pfu/mL) % inhibition
TNapPS 3.5 × 105 98 2.6 × 105 98
TAnthPS 3.0 × 106 81 5.8 × 105 96
CuHPIX 1.1 × 106 93 4.5 × 105 97
CuPcS(3444) 6.3 × 106 60 4.1 × 106 74
ZnPPIX 2.5 × 105 98 1.0 × 105 99
aCV-1 cells were infected with the WR strain at 2.5 pfu/cell and then media containing compounds at 50 or 25 µg/mL were added; at 16 h post-
infection, the cells and media were collected for virus titration by plaque assay. % inhibition = (1 - TA/TB) × 100 where TA is the average virus titer 
in the presence of the tetrapyrrole and TB is the virus titer where no compound was added (control). Virus titer in the control was 1.6 × 107 pfu/
mL. Data are means of duplicate experiments.
Table 5: Inhibition of virus yield after removal of tetrapyrroles before cell lysis.a
Compound Concentration
25 µg/mL 50 µg/mL
titer (pfu/mL) % inhibition titer (pfu/mL) % inhibition
TNapPS 3.5 × 105 73 ± 16 1.0 × 105 92 ± 1
TAnthPS 1.2 × 106 39 ± 13 7.5 × 105 67 ± 15
CuHPIX 1.3 × 106 33 ± 9 6.3 × 105 71 ± 4
CuPcS(3444) 9.3 × 105 49 ± 21 8.3 × 105 59 ± 2
ZnPPIX 7.2 × 105 65 ± 0.3 6.4 × 105 70 ± 4
aCV-1 cells were infected at 2.5 pfu/cell and then treated with compounds at 50 or 25 µg/mL; at 16 h post-infection, the medium was removed and 
cells were washed and harvested for virus titration by plaque assay. Virus titer in the control was 2.1 × 106 pfu/mL. Data are expressed as means ± 
std of triplicate experiments, each replicated twice. % inhibition was calculated as described in Table 4.BMC Infectious Diseases 2003, 3 http://www.biomedcentral.com/1471-2334/3/9
Page 8 of 10
(page number not for citation purposes)
tetrapyrrole with resulting production of free radicals and
singlet oxygen. In the current study, inhibition of vaccinia
infection is not due to photoactivation of the tetrapyr-
roles, as shown by two aspects of the experiments. First,
there was little exposure to light during experiments, with
no additional irradiation. Second, we observed that the
extent of inactivation was not a function of the spin state
(diamagnetic or paramagnetic) for metal chelates of the
porphyrins and phthalocyanines. Only diamagnetic
tetrapyrroles are able to inhibit viruses via photoinactiva-
tion; the excited states of the paramagnetic derivatives
have short half-lives and do not give significant amounts
of free radicals or singlet oxygen. Tetrapyrroles previously
have been reported to inhibit certain other viruses by
mechanisms not involving photoactivation. A cationic
phthalocyanine was reported to inhibit human rhinovirus
type 5 (RV-5) infection [21]. Selected porphyrin deriva-
tives inhibit specific viral targets including retroviral
reverse transcriptase [22–26] and HIV-1 protease [27].
In previous studies of the antiviral effects of porphyrins,
Song et al. investigated the antiviral effects of Fe meso-tet-
rakis(3,4-disulfonatomesityl)porphyrin (FeTMPS), and
meso-tetra(4-carboxyphenyl)porphyrin (TPPC) and its
iron and nickel chelates for a variety of viruses [28]. EC50s
were generally 20 µg/mL or greater for VV, VSV, HSV-1,
HSV-2, Coxsackie virus B4 and poliovirus-1. FeTMPS
showed activity in this range also for parainfluenza-3, reo-
virus-1, and Semliki forest virus. FeTMPS was more active
for sindbis virus, VZV and CMV, with EC50s of 5 to 25 µg/
mL. Fe and Ni TPPC were also quite active against CMV.
Porphyrins and metalloporphyrins have also been shown
to have antiviral activity against HIV [23–38]. Previous
studies indicated that some porphyrins inhibit the
interaction between the virus envelope protein and its
receptors [28,31–38]. We have shown also that
porphyrins block infection by HIV-1 and that this activity
appears to be a result of an interaction with the envelope
protein [38]. In this regard, the compounds that were
active in blocking infection by HIV-1 tended to be
sulfonated compounds or other negatively charged com-
pounds. In the present study, it is of interest that the
uncharged molecule TPP[2,6-(OH)2] was one of the most
active compounds tested. This result indicates that the
activity of this compound with VV is not merely a reflec-
tion of an interaction between a negatively charged mole-
cule and positively charged sites on the viral surface, but
that other structural features are important for interaction
with viral proteins.
Although the WR and IHD-J strains exhibited similar sen-
sitivity to most of the compounds tested, some differences
in their relative sensitivity was observed. The WR strain
was 3- to 6-fold less sensitive than IHD-J to several com-
pounds including TAnthPS, CuHPIX, and TPP2FS, but
was about 3-fold more sensitive to inhibition by
TPP[2,6(OH)2]. These results support the conclusion that
the compounds block infection by interacting with spe-
cific viral protein(s), and that strain-specific differences in
protein structures determine the differences in sensitivi-
ties to specific compounds. The sensitivity of the activity
to relatively small structural changes in our work indicates
either that amphiphilicity and steric and specific axial lig-
and effects significantly control binding to the virion tar-
get, or that more than one mechanism of inhibition is
operational.
EC50 data obtained from both viruses studied ranged from
0.05 to 40 µM. This range is comparable to that observed
for other compounds active against vaccinia. For example,
cidofovir, an acyclic nucleoside with activity against a vari-
Table 6: Inhibition of virus yield during multiple cycle infection.a
Compound Concentration
25 µg/mL 50 µg/mL
titer (pfu/mL) % inhibition titer (pfu/mL) % inhibition
TNapPS 3.3 × 104 87 ± 5 1.3 × 104 95 ± 2
TAnthPS 4.7 × 104 81 ± 5 2.7 × 104 89 ± 6
CuHPIX 5.0 × 104 80 ± 2 2.3 × 104 91 ± 2
CuPcS(3444) 2.1 × 104 92 ± 3 2.4 × 104 90 ± 2
ZnPPIX 2.1 × 104 92 ± 1 3.2 × 103 99 ± 7
aCV-1 cells were infected at 0.001 pfu/cell and then treated with compounds at 50 or 25 µg/mL; at 24 h post-infection, the media were removed 
and cells washed and harvested for virus titration by plaque assay. % inhibition = (1 - TA/TB) × 100 where TA is the average virus titer in the pres-
ence of the tetrapyrrole and TB is the virus titer where no compound was added (control). Virus titer in the control was 2.5 × 105 pfu/mL. Data are 
expressed as means ± std of triplicate experiments, each replicated twice.BMC Infectious Diseases 2003, 3 http://www.biomedcentral.com/1471-2334/3/9
Page 9 of 10
(page number not for citation purposes)
ety of DNA viruses, used clinically in some instances [39],
has been shown to be effective against a number of
poxviruses with the following EC50 values: 2.3 µM (camel-
pox), 46.2 µM (vaccinia), 27 µM (monkeypox) and 58 µM
(cowpox) [40,41]. Other classes of compounds have been
tested for their effectiveness against vaccinia virus includ-
ing the IMP dehydrogenase inhibitors (EC50 4 – 100 µg/
mL), OMP decarboxylase inhibitors (0.02 – 15 µg/mL),
and polyanionic compounds (0.1 – 20 µg/mL) [6].
In conclusion, we observed that both porphyrins and
phthalocyanines have substantial antiviral activity against
vaccinia virus. Examples of the natural porphyrin, sul-
fonated tetraphenylporphyrin, neutral tetraphenylpor-
phyrin and sulfonated phthalocyanine classes were all
found to be active. These results, as well as the high ther-
apeutic ratios observed, indicate that these compounds
represent attractive candidates as antiviral agents to con-
trol poxvirus infection.
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